Cargando…

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

BACKGROUND: Persistence on-treatment with antimuscarinics in patients with overactive bladder (OAB) is reported to be sub-optimal. This retrospective, longitudinal, observational cohort study assessed treatment persistence with β(3)-adrenoceptor agonists (i.e. mirabegron) and antimuscarinics, both c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazir, Jameel, Hakimi, Zalmai, Guelfucci, Florent, Khemiri, Amine, Fatoye, Francis, Blázquez, Ana María Mora, González, Marta Hernández
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122705/ https://www.ncbi.nlm.nih.gov/pubmed/30180826 http://dx.doi.org/10.1186/s12894-018-0390-z

Ejemplares similares

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
por: Drake, Marcus J., et al.
Publicado: (2017)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
por: Carlson, Kevin V., et al.
Publicado: (2019)

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
por: Hoffman, Veena, et al.
Publicado: (2021)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
por: Arlandis-Guzman, Salvador, et al.
Publicado: (2011)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
por: Desroziers, Katia, et al.
Publicado: (2013)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
por: Khullar, Vik, et al.
Publicado: (2013)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
por: Kosilov, Kirill Vladimirovich, et al.
Publicado: (2017)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p66br6hfo7svcjf55en99v3u9r